Drug-induced liver injury: what was new in 2008?

Bibliography

• Zimmerman HJ. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd edition. Philadelphia PA: Lippincott Williams and Wilkins, 1999
   Google Scholar
• Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-9
   PubMed Web of Science ®Google Scholar
• Lewis JH, Kleiner DE. Hepatic injury due to drugs, chemicals and toxins. In: Burt AD, Portmann BC, Ferrell LD, editors. MacSween′s pathology of the liver, 5th edition. Amsterdam: Churchill Livingstone Elsevier; 2006. p. 649-759
   Google Scholar
• Lewis JH. Liver disease caused by anesthetics, toxins, and herbal preparations. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran′s gastrointestinal and liver disease: pathophysiology/diagnosis/management, 8th edition. Philadelphia: Saunders Elsevier, 2006. p. 1853-68
   Google Scholar
• Carey EJ, Vargas HE, Douglas DD, et al. Inpatient admissions for drug-induced liver injury: results from a single center. J Dig Dis Sci 2008;53(7):1977-82
   PubMed Web of Science ®Google Scholar
• Galan MV, Potts JA, Siverman AL, et al. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol 2005;39:64-7
   PubMed Web of Science ®Google Scholar
• Meier Y, Cavallaro M, Roos M, et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005;61:135-43
   PubMed Web of Science ®Google Scholar
• De Valle MB, Av Klinteberg V, Alem N, et al. Drug induced liver injury in a Swedish university hospital out-patient hepatology clinic.
   Google Scholar
• Vuppalanchi R, Liangpunsakul S, Chalasani N, et al. Etiology of new onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol 2007;102:558-62
   PubMed Web of Science ®Google Scholar
• Hussaini SH, O′Brien CS, Despott EJ, et al. Antiobiotic therapy: a major cause of drug-induced jaundice in southwest Englang. Eur J Gastroenterol Hepatol 2007;19:15-20
   PubMed Web of Science ®Google Scholar
• Akhtar AJ, Shaheen M. Jaundice in African-American and Hispanic patients with AIDS. J Natl Med Assoc 2007;99:1381-5
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Lucena MI, Fernandez C, et al. Drug induced injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology 2005;129:512-21
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug induced liver disease. Hepatology 2005;42:481-9
   PubMed Web of Science ®Google Scholar
• Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924-34
   PubMed Web of Science ®Google Scholar
• Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007;11:477-505
   PubMedGoogle Scholar
• Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001;33:308-10
   PubMed Web of Science ®Google Scholar
• Rochling FA, Zetterman RK. Do hepatotoxicity registries have a role in health care? Gastroenterology 2008;135:1847-50
   PubMed Web of Science ®Google Scholar
• Dalton HR, Fellows HJ, Stableforth W, et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007;26:1429-35
   PubMed Web of Science ®Google Scholar
• FDA Safety Alerts for Human Medical Products accessed at http://www.fda.gov/medwatch/safety.htm
   Google Scholar
• Srinivasan S, Parsa V, Liu CY, et al. Trastuzumab-induced hepatotoxicity. Ann Pharmacother 2008;42:1497-501
   PubMed Web of Science ®Google Scholar
• Schramm C, Schuch G, Lohse AW. Sorafenib-induced liver failure. Am J Gastroenterol 2008;103:2162-3
   PubMed Web of Science ®Google Scholar
• Shpaner A, Li W, Ankoma-Sey V, et al. Drug-induced liver injury: hepatotoxicity of quetiapine revisited. Eur J Gastroenterol Hepatol 2008;20:1106-9
   PubMed Web of Science ®Google Scholar
• Farah M, Al Rashidi A, Owen DA, et al. Granulomatous hepatitis associated with etanercept therapy. J Rheumatol 2008;35:349-51
   PubMed Web of Science ®Google Scholar
• Leak AM, Rincon-Aznar B. Hepatotoxicity associated with etanercept in psoriatic arthritis. J Rheumatol 2008;35:2286-7
   PubMedGoogle Scholar
• Mueller EW, Rockey ML, Rashkin MC. Sunitinib-related fulminant hepatic failure: case report and review of the literature. Pharmacotherapy 2008;28:1066-70
   PubMed Web of Science ®Google Scholar
• Watkins PB. Drug-induced liver injury network. Am J Gastroenterol 2008;103:1574-5
   PubMed Web of Science ®Google Scholar
• Guéant JL, Guéant-Rodriguez RM, Gastin IA, et al. Pharmacogenetic determinants of immediate and delayed reactions of drug hypersensitivity. Curr Pharm Des 2008;14:2770-7
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Pharmacogenomic Biomarkers for Prediction of Severe Adverse Drug Reactions. N Engl J Med 2008;358:637-9
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79
   PubMed Web of Science ®Google Scholar
• Schackman BR, Scott CA, Walensky RP, et al. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008;22:2025-33
   PubMed Web of Science ®Google Scholar
• Young B, Squires K, Patel P, et al. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS 2008;22:1673-5
   PubMed Web of Science ®Google Scholar
• Colombo S, Rauch A, Rotger M, et al. The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J Infect Dis 2008;198:864-7
   PubMed Web of Science ®Google Scholar
• Day C. European Hepatology Networks: UK. Drug-induced liver injury: Standardization of nomenclature and causality assessment. NIH workshop Dec 1-2, 2008. Lister Hill Auditorium: Bethesda, MD. p. 12
   Google Scholar
• Andrews E, Daly AK. Flucloxacillin-induced liver injury. Toxicology 2008;254:158-63
   PubMed Web of Science ®Google Scholar
• Ozer J, Ratner M, Shaw M. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008;245:194-205
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 2008;358:637-9
   PubMed Web of Science ®Google Scholar
• Pachkoria K, Lucena MI, Molokhia M, et al. Genetic and molecular factors in drug-induced liver injury: a review. Curr Drug Saf 2007;2:97-112
   PubMedGoogle Scholar
• Makarova SI. Human N-acetyltransferases and drug-induced hepatotoxicity. Curr Drug Metab 2008;9:538-45
   PubMed Web of Science ®Google Scholar
• Lucena MI, Andrade RJ, Martínez C, et al. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008;48:588-96
   PubMed Web of Science ®Google Scholar
• Miller TJ, Knapton A, Adeyemo O, et al. Cytochrome c: a non-invasive biomarker of drug-induced liver injury. J Appl Toxicol 2008;28:815-28
   PubMed Web of Science ®Google Scholar
• Xu JJ, Henstock PV, Dunn MC, et al. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 2008;105:97-105
   PubMed Web of Science ®Google Scholar
• Thum T, Borlak J. Detection of early signals of hepatotoxicity by gene expression profiling studies with cultures of metabolically competent human hepatocytes. Arch Toxicol 2008;82:89-101
   PubMed Web of Science ®Google Scholar
• Barros SA, Martin RB. Predictive toxicogenomics in preclinical discovery. Methods Mol Biol 2008;460:89-112
   PubMedGoogle Scholar
• Antoine DJ, Williams DP, Park BK. Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science. Expert Opin Drug Metab Toxicol 2008;4:1415-27
   PubMed Web of Science ®Google Scholar
• Tuschl G, Lauer B, Mueller SO. Primary hepatocytes as a model to analyze species-specific toxicity and drug metabolism. Expert Opin Drug Metab Toxicol 2008;4:855-70
   PubMed Web of Science ®Google Scholar
• Boelsterli UA, Hsiao CJ. The heterozygous Sod2( + /-) mouse: modeling the mitochondrial role in drug toxicity. Drug Discov Today 2008;13:982-8
   PubMed Web of Science ®Google Scholar
• Lammert C, Einarsson S, Saha C, et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008;47:2003-9
   PubMed Web of Science ®Google Scholar
• Senior JR. What is idiosyncratic hepatotoxicity? What is it not? Hepatology 2008;47:1813-5
   PubMed Web of Science ®Google Scholar
• Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 2007;47:513-39
   PubMed Web of Science ®Google Scholar
• Gupta NK, Lewis JH. Review article: The use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther 2008;28:1021-41
   PubMed Web of Science ®Google Scholar
• Flores YN, Yee HF Jr, Leng M, et al. Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004. Am J Gastroenterol 2008;103:2231-8
   PubMed Web of Science ®Google Scholar
• Lewis JH, Mortensen ME, Zweig S, et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007;46:1453-63
   PubMed Web of Science ®Google Scholar
• Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005;329:62-5
   PubMed Web of Science ®Google Scholar
• Chalasani N, Aljadhey H, Kesterson J, et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-92
   PubMed Web of Science ®Google Scholar
• Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10
   PubMed Web of Science ®Google Scholar
• García-Romero D, Anastassiou J, Hart G, et al. High prevalence of abnormal alanine and aspartate aminotransferases in a “worried-well” population in the United Kingdom: rationale for a liver screening program? Hepatology 2008;48:1729-30
   PubMedGoogle Scholar
• Halegoua-De Marzio D, Navarro VJ. Drug-induced hepatotoxicity in humans. Curr Opin Drug Discov Devel 2008;11:53-9
   PubMed Web of Science ®Google Scholar
• FDA Draft Guidance for Industry October 2007. Drug-Induced Liver Injury: Premarketing Clinical Evaluation accessed by http://www.fda.gov/cder/Guidance/7507dft.pdf
   Google Scholar
• European Medicines Agency. Non-clinical guideline on drug-induced hepatotoxicity; European Medicines Agency, DRAFT 2008. Accessed at www.emea.europa.eu
   Google Scholar
• García-Cortés M, Lucena MI, Pachkoria K, et al. Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 2008;27:780-9
   PubMed Web of Science ®Google Scholar
• Lewis JH, Larrey D, Olsson R, et al. Utility of the Roussel Uclaf Causality Assessment Method (RUCAM) to analyze the hepatic findings in a clinical trial program: evaluation of the direct thrombin inhibitor ximelagatran. Int J Clin Pharmacol Ther 2008;46:327-39
   PubMed Web of Science ®Google Scholar
• Rochon J, Protiva P, Seeff LB, et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008;48:1175-83
   PubMed Web of Science ®Google Scholar
• Lucena MI, García-Cortés M, Cueto R, et al. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol 2008;22:141-58
   PubMed Web of Science ®Google Scholar
• Etwel FA, Rieder MJ, Bend JR, et al. A surveillance method for the early identification of idiosyncratic adverse drug reactions. Drug Saf 2008;31:169-80
   PubMed Web of Science ®Google Scholar
• Heard KJ. Acetylcysteine for acetaminophen poisoning. N Engl J Med 2008;359:285-92
   PubMed Web of Science ®Google Scholar
• Fontana RJ. Acute liver failure due to drugs. Semin Liver Dis 2008;28:175-87
   PubMed Web of Science ®Google Scholar
• Lee WM, Squires RH Jr, Nyberg SL, et al. Summary of a workshop. Hepatology 2008;47:1401-15
   PubMed Web of Science ®Google Scholar
• Murray KF, Hadzic N, Wirth S, et al. Drug-related hepatotoxicity and acute liver failure. J Pediatr Gastroenterol Nutr 2008;47:395-405
   PubMed Web of Science ®Google Scholar
• Pearce B, Grant IS. Acute liver failure following therapeutic paracetamol administration in patients with muscular dystrophies. Anaesthesia 2008;63:89-91
   PubMed Web of Science ®Google Scholar
• Smith SW, Howland MA, Hoffman RS, et al. Acetaminophen overdose with altered acetaminophen pharmacokinetics and hepatotoxicity associated with premature cessation of intravenous N-acetylcysteine therapy. Ann Pharmacother 2008;42:1333-9
   PubMed Web of Science ®Google Scholar
• Abdel-Zaher AO, Abdel-Hady RH, Mahmoud MM, et al. The potential protective role of alpha-lipoic acid against acetaminophen-induced hepatic and renal damage. Toxicology 2008;243:261-70
   PubMed Web of Science ®Google Scholar
• Terneus MV, Brown JM, Carpenter AB, et al. Comparison of S-adenosyl-L-methionine (SAMe) and N-acetylcysteine (NAC) protective effects on hepatic damage when administered after acetaminophen overdose. Toxicology 2008;244:25-34
   PubMed Web of Science ®Google Scholar
• Holt MP, Cheng L, Ju C. Identification and characterization of infiltrating macrophages in acetaminophen-induced liver injury. J Leukoc Biol 2008;84:1410-21
   PubMed Web of Science ®Google Scholar
• Bajt ML, Yan HM, Farhood A, et al. Plasminogen activator inhibitor-1 limits liver injury and facilitates regeneration after acetaminophen overdose. Toxicol Sci 2008;104:419-27
   PubMed Web of Science ®Google Scholar
• Donthamsetty S, Bhave VS, Mitra MS, et al. Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARalpha with clofibrate. Toxicol Appl Pharmacol 2008;230:327-37
   PubMed Web of Science ®Google Scholar
• Aleksunes LM, Slitt AL, Maher JM, et al, Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. Toxicol Appl Pharmacol 2008;226:74-83
   PubMed Web of Science ®Google Scholar
• Aleksunes LM, Campion SN, Goedken MJ, et al. Acquired resistance to acetaminophen hepatotoxicity is associated with induction of multidrug resistance-associated protein 4 (Mrp4) in proliferating hepatocytes. Toxicol Sci 2008;104:261-73
   PubMed Web of Science ®Google Scholar
• Campion SN, Johnson R, Aleksunes LM, et al. Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function. Am J Physiol Gastrointest Liver Physiol 2008;295:G294-304
   PubMed Web of Science ®Google Scholar
• Yalçin S, Bilgili A, Onbasilar I, et al. Synergistic action of sodium selenite and N-acetylcysteine in acetaminophen-induced liver damage. Hum Exp Toxicol 2008;27:425-9
   PubMed Web of Science ®Google Scholar
• Palmer GM, Atkins M, Anderson BJ, et al. I.V. acetaminophen pharmacokinetics in neonates after multiple doses. Br J Anaesth 2008;101:523-30
   PubMed Web of Science ®Google Scholar
• Ding GK, Buckley NA. Evidence and consequences of spectrum bias in studies of criteria for liver transplant in paracetamol hepatotoxicity. QJM 2008;101:723-9
   PubMed Web of Science ®Google Scholar
• Ali FM, Boyer EW, Bird SB, et al. Estimated risk of hepatotoxicity after an acute acetaminophen overdose in alcoholics. Alcohol 2008;42:213-8
   PubMed Web of Science ®Google Scholar
• Bartels S, Sivilotti M, Crosby D, et al. Are recommended doses of APAP hepatotoxic for recently abstienent alcoholics? A randomized trial. Clin Toxicol 2008;46:243-9
   PubMed Web of Science ®Google Scholar
• Waring WS, Robinson OD, Stephen AF, et al. Does the patient history predict hepatotoxicity after acute paracetamol overdose? QJM 2008;101:121-5
   PubMed Web of Science ®Google Scholar
• Waring WS, Stephen AF, Malkowska AM, et al. Acute ethanol coingestion confers a lower risk of hepatotoxicity after deliberate acetaminophen overdose. Acad Emerg Med 2008;15:54-8
   PubMed Web of Science ®Google Scholar
• Myers RP, Shaheen AA, Li B, et al. Impact of liver disease, alcohol abuse, and unintentional ingestions on the outcomes of acetaminophen overdose. Clin Gastroenterol Hepatol 2008;6:918-25
   PubMed Web of Science ®Google Scholar
• Field KM, Dow C, Michael M. Part I: Liver function in oncology: biochemistry and beyond. Lancet Oncol 2008;9:1092-101
   PubMed Web of Science ®Google Scholar
• Field KM, Michael M. Part II: Liver function in oncology: towards safer chemotherapy use. Lancet Oncol 2008;9:1181-90
   PubMed Web of Science ®Google Scholar
• Domènech E, Mañosa M, Navarro M, et al. Long-term methotrexate for Crohn′s disease: safety and efficacy in clinical practice. J Clin Gastroenterol 2008;42:395-9
   PubMed Web of Science ®Google Scholar
• Taylor WJ, Korendowych E, Nash P, et al. Drug use and toxicity in psoriatic disease: focus on methotrexate. J Rheumatol 2008;35:1454-7
   PubMed Web of Science ®Google Scholar
• Ranganathan P, Culverhouse R, Marsh S, et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008;35:572-9
   PubMed Web of Science ®Google Scholar
• Leong RW, Gearry RB, Sparrow MP. Thiopurine hepatotoxicity in IBD: the role for adding allopurinol. Expert Opin Drug Saf 2008;7(5):607-16
   PubMed Web of Science ®Google Scholar
• Ansari A, Elliott T, Baburajan B, et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:734-41
   PubMed Web of Science ®Google Scholar
• Avins AL, Manos MM, Ackerson L, et al. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study. Drug Saf 2008;31:325-34
   PubMed Web of Science ®Google Scholar
• Tuteja S, Pyrsopoulos NT, Wolowich WR, et al. Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation. Pharmacotherapy 2008;28:1188-93
   PubMed Web of Science ®Google Scholar
• Bays H, Sapre A, Taggart W, et al. Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Curr Med Res Opin 2008;24:2953-66
   PubMed Web of Science ®Google Scholar
• Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008;197:S279-93
   PubMed Web of Science ®Google Scholar
• Brück S, Witte S, Brust J, et al. Hepatotoxicity in patients prescribed efavirenz or nevirapine. Eur J Med Res 2008;13:343-8
   PubMed Web of Science ®Google Scholar
• Shah T, Lampiris H, Vu M, et al. Resolution of hepatitis C virus-induced steatosis improves tolerability of antiretroviral drugs associated with hepatotoxicity in an HIV-infected individual. J Infect Dis 2008;197:932-3
   PubMed Web of Science ®Google Scholar
• Hoffmann CJ, Charalambous S, Martin DJ, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008;47:1479-85
   PubMed Web of Science ®Google Scholar
• Medrano J, Barreiro P, Tuma P, et al. Risk for immune-mediated liver reactions by nevirapine revisited. AIDS Rev 2008;10:110-5
   PubMed Web of Science ®Google Scholar
• Chan-Tack KM, Struble KA, Birnkrant DB. Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA′s Adverse Event Reporting System. AIDS Patient Care STDS 2008;22:843-50
   PubMed Web of Science ®Google Scholar
• Akhtar MA, Mathieson K, Arey B, et al. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis. Eur J Gastroenterol Hepatol 2008;20:1194-204
   PubMed Web of Science ®Google Scholar
• Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006; 174:935-52
   Google Scholar
• Liu Q, Garner P, Wang Y, et al. Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: systematic review of ingredients and evaluation studies. BMC Public Health 2008;8:365
   PubMed Web of Science ®Google Scholar
• Marzuki OA, Fauzi AR, Ayoub S, et al. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singapore Med J 2008;49:688-93
   PubMed Web of Science ®Google Scholar
• Chang KC, Leung CC, Yew WW, et al. Hepatotoxicity of pyrazinamide: cohort and case-control analyses. Am J Respir Crit Care Med 2008;177:1391-6
   PubMed Web of Science ®Google Scholar
• Sun F, Chen Y, Xiang Y, et al. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2008;12:994-1002
   PubMed Web of Science ®Google Scholar
• Roy PD, Majumder M, Roy B. Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics 2008;9:311-21
   PubMed Web of Science ®Google Scholar
• Possuelo LG, Castelan JA, de Brito TC, et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008;64:673-81
   PubMed Web of Science ®Google Scholar
• Leiro V, Fernández-Villar A, Valverde D, et al. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 2008;28:835-9
   PubMed Web of Science ®Google Scholar
• Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008;149:689-97
   PubMed Web of Science ®Google Scholar
• Shen C, Meng Q, Zhang G, et al. Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like cultures. Br J Pharmacol 2008;153:784-91
   PubMed Web of Science ®Google Scholar
• Lobato MN, Jereb JA, Starke JR. Unintended consequences: mandatory tuberculin skin testing and severe isoniazid hepatotoxicity. Pediatrics 2008;121:e1732-3
   PubMedGoogle Scholar
• Eminzade S, Uraz F, Izzettin FV. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals. Nutr Metab (Lond) 2008;5:18
   Google Scholar
• Fontana RJ, Shakil AO, Greenson JK, et al. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci 2005;50:1785-90
   PubMed Web of Science ®Google Scholar
• Devereaux BM, Crawford DH, Purcell P, et al. Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Eur J Clin Pharmacol 1995;49:81-5
   Web of Science ®Google Scholar
• Chen Y, Guo JJ, Healy DP, et al. Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms. Ann Pharmacother 2008;42:1791-6
   PubMed Web of Science ®Google Scholar
• Brinker AD, Wassel RT, Lyndly J, et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 2009;49:250-7
   PubMed Web of Science ®Google Scholar
• Bolesta S, Roslund BP. Elevated hepatic transaminases associated with telithromycin therapy: a case report and literature review. Am J Health Syst Pharm 2008;65:37-41
   PubMed Web of Science ®Google Scholar
• Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 2003;98:175-9
   PubMed Web of Science ®Google Scholar
• Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology 2005;41:237-46
   PubMed Web of Science ®Google Scholar
• Snow KL, Moseley RH. Effect of thiazolidinediones on bile acid transport in rat liver. Life Sci 2007;80:732-40
   PubMed Web of Science ®Google Scholar
• Lee YH, Chung MC, Lin Q, et al. Troglitazone-induced hepatic mitochondrial proteome expression dynamics in heterozygous Sod2(+/-) mice: two-stage oxidative injury. Toxicol Appl Pharmacol 2008;231:43-51
   PubMed Web of Science ®Google Scholar
• Julie NL, Julie IM, Kende AI, et al. Mitochondrial dysfunction and delayed hepatotoxicity: another lesson from troglitazone. Diabetologia 2008;51:2108-16
   PubMed Web of Science ®Google Scholar
• Chitturi S, Farrell GC. Hepatotoxic slimming aids and other herbal hepatotoxins. J Gastroenterol Hepatol 2008;23:366-73
   PubMed Web of Science ®Google Scholar
• Herrera S, Bruguera M. Hepatotoxicity induced by herbs and medicines used to induce weight loss. Gastroenterol Hepatol 2008;31:447-53
   PubMedGoogle Scholar
• Manso G, López-Rivas L, Duque JM, et al. Spanish reports of hepatotoxicity associated with Herbalife products. J Hepatol 2008;49:289-90; author reply 290-1
   PubMed Web of Science ®Google Scholar
• Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J Hepatol 2005;43:901-10
   PubMed Web of Science ®Google Scholar
• Dhiman RK, Chawla YK. Herbal medicines for liver diseases. Dig Dis Sci 2005;50:1807-12
   PubMed Web of Science ®Google Scholar
• Sarma DN, Barrett ML, Chavez ML, et al. Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf 2008;31:469-84
   PubMed Web of Science ®Google Scholar
• Gloro R, Hourmand-Ollivier I, Mosquet B, et al. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur J Gastroenterol Hepatol 2005;17:1135-7
   PubMed Web of Science ®Google Scholar
• Molinari M, Watt KD, Kruszyna T. Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl 2006;12:1892-5
   PubMed Web of Science ®Google Scholar
• Teschke R, Schwarzenboeck A, Hennermann KH. Causality assessment in hepatotoxicity by drugs and dietary supplements. Br J Clin Pharmacol 2008;66:758-66
   PubMed Web of Science ®Google Scholar
• Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008;20:1182-93
   PubMed Web of Science ®Google Scholar
• Teschke R, Schwarzenboeck A, Akinci A. Kava hepatotoxicity: a European view. N Z Med J 2008;121:90-8
   PubMedGoogle Scholar
• García-Cortés M, Lucena MI, Andrade RJ, et al. Is the Naranjo probability scale accurate enough to ascertain causality in drug-induced hepatotoxicity? Ann Pharmacother 2004;38:1540-1
   PubMed Web of Science ®Google Scholar
• Lee CH, Wang JD, Chen PC. Case-crossover study of hospitalization for acute hepatitis in Chinese herb users. J Gastroenterol Hepatol 2008;23:1549-55
   PubMed Web of Science ®Google Scholar
• Foti RS, Dickmann LJ, Davis JA, et al. Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements. Xenobiotica 2008;38:264-80
   PubMed Web of Science ®Google Scholar
• Available from: www.cfsan.fda.gov/˜dms/ds-warn.html
   Google Scholar
• Lüde S, Török M, Dieterle S, et al. Hepatocellular toxicity of kava leaf and root extracts. Phytomedicine 2008;15:120-31
   PubMed Web of Science ®Google Scholar
• Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5147a1.htm
   Google Scholar
• Grillo MP, Hua F, March KL, et al. Gamma-glutamyltranspeptidase-mediated degradation of diclofenac-S-acyl-glutathione in vitro and in vivo in rat. Chem Res Toxicol 2008;21:1933-8
   PubMed Web of Science ®Google Scholar
• Grillo MP, Ma J, Teffera Y, et al. A novel bioactivation pathway for 2-[2-(2,6-dichlorophenyl)aminophenyl]ethanoic acid (diclofenac) initiated by cytochrome P450-mediated oxidative decarboxylation. Drug Metab Dispos 2008;36:1740-4
   PubMed Web of Science ®Google Scholar
• Walker SL, Kennedy F, Niamh N, et al. Nimesulide associated fulminant hepatic failure. Pharmacoepidemiol Drug Saf 2008;17:1108-12
   PubMed Web of Science ®Google Scholar
• Abraham C, Hart J, Locke SM, et al. A case of indometacin-induced acute hepatitis developing into chronic autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 2008;5:172-6
   PubMedGoogle Scholar
• Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 2008;118:281-90
   PubMed Web of Science ®Google Scholar
• Moeller KE, Wei L, Jewell AD, et al. Acute hepatotoxicity associated with lamotrigine. Am J Psychiatry 2008;165:539-40
   PubMed Web of Science ®Google Scholar
• Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008;31:345-54
   PubMed Web of Science ®Google Scholar
• McFarland R, Hudson G, Taylor RW, et al. Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1). Arch Dis Child 2008;93:151-3
   PubMed Web of Science ®Google Scholar
• Reuben A. Hy′s Law. Hepatology 2004;39:574-8
   PubMed Web of Science ®Google Scholar
• Lewis JH. ‘Hy′s Law, the Rezulin Rule,′ and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidmiol Drug Saf 2006;15:221-9
   PubMed Web of Science ®Google Scholar
• Temple R. Hy′s law: predicting serious hepatotoxicity. Pharmacoepidmiol Drug Saf 2006;15:241-3
   PubMed Web of Science ®Google Scholar
• Abusin S, Johnson S. Sulfamethoxazole/Trimethoprim induced liver failure: a case report. Cases J 2008;1:44
   PubMedGoogle Scholar
• Ford TJ, Dillon JF. Minocycline hepatitis. Eur J Gastroenterol Hepatol 2008;20:796-9
   PubMed Web of Science ®Google Scholar
• Chen J, Ahmad J. Cefdinir-induced hepatotoxicity: potential hazards of inappropriate antibiotic use. J Gen Intern Med 2008;23:1914-6
   PubMed Web of Science ®Google Scholar
• Whitt KN, Ward SC, Deniz K, et al. Cholestatic liver injury associated with whey protein and creatine supplements. Semin Liver Dis 2008;28:226-31
   PubMed Web of Science ®Google Scholar
• Soyuncu S, Cete Y, Nokay AE. Portal vein thrombosis related to Cassia angustifolia. Clin Toxicol (Phila) 2008;46:774-7
   PubMed Web of Science ®Google Scholar
• Cohen DL, Del Toro Y. A case of valerian-associated hepatotoxicity. J Clin Gastroenterol 2008;42:961-2
   PubMed Web of Science ®Google Scholar
• Poon WT, Chau TL, Lai CK, et al. Hepatitis induced by Teucrium viscidum. Clin Toxicol (Phila) 2008;46:819-22
   PubMed Web of Science ®Google Scholar
• Dara L, Hewett J, Lim JK. Hydroxycut hepatotoxicity: A case series and review of liver toxicity from herbal weight loss supplements. World J Gastroenterol 2008;14:6999-7004
   PubMed Web of Science ®Google Scholar
• Stadlbauer V, Weiss S, Payer F, et al. Herbal does not at all mean innocuous: the sixth case of hepatotoxicity associated with morinda citrifolia (noni). Am J Gastroenterol 2008;103:2406-7
   PubMed Web of Science ®Google Scholar
• Shah NL, Zacharias I, Khettry U, et al. Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases. Clin Gastroenterol Hepatol 2008;6:255-8
   PubMed Web of Science ®Google Scholar
• Lee MH, Graham GG, Williams KM, et al. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf 2008;31:643-65. Review
   Google Scholar
• Veltkamp SA, Pluim D, van Tellingen O, et al. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. Drug Metab Dispos 2008;36:1606-15
   PubMed Web of Science ®Google Scholar
• Christopeit M, Eikam M, Behre G. Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity. Mycoses 2008;51 Suppl 1:19-24
   PubMed Web of Science ®Google Scholar
• O′Bryant CL, Flaig TW, Utz KJ. Bicalutamide-associated fulminant hepatotoxicity. Pharmacotherapy 2008;28:1071-5
   PubMed Web of Science ®Google Scholar
• Castro Beza I, Sánchez Ruiz J, Peracaula Espino FJ, et al. Drug-related hepatotoxicity and hepatic failure following combined androgen blockade. Clin Transl Oncol 2008;10:591-2
   PubMed Web of Science ®Google Scholar
• Chan AL, Hsieh HJ, Hsieh YA, et al. Fatal amiodarone-induced hepatotoxicity: a case report and literature review. Int J Clin Pharmacol Ther 2008;46:96-101
   PubMed Web of Science ®Google Scholar
• Babatin M, Lee SS, Pollak PT. Amiodarone hepatotoxicity. Curr Vasc Pharmacol 2008;6:228-36
   PubMed Web of Science ®Google Scholar
• Arkun A, Van Deusen SK, Grau T, et al. Hepatic Dysfunction and Neurotoxicity in a Patient Receiving Long-Term Low-Dose Amiodarone Therapy. J Emerg Med 2008
   PubMedGoogle Scholar
• Jobanputra P, Amarasena R, Maggs F, et al. Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord 2008;9:48
   PubMed Web of Science ®Google Scholar
• Ho V, Stewart M, Boyd P. Cholestatic hepatitis as a possible new side-effect of oxycodone: a case report. J Med Case Reports 2008;2:140
   PubMedGoogle Scholar
• Wiper A, Schmitt M, Roberts DH. Clopidogrel-induced hepatotoxicity. J Postgrad Med 2008;54:152
   PubMed Web of Science ®Google Scholar
• Wolfhagen FH, Vermeulen HG, de Man RA, et al. Initially obscure hepatotoxicity attributed to sildenafil. Eur J Gastroenterol Hepatol 2008;20:710-2
   PubMed Web of Science ®Google Scholar
• Alotaibi WM. Severe hepatic dysfunction after sevoflurane exposure. Saudi Med J 2008;29:1344-6
   PubMed Web of Science ®Google Scholar
• Lewandowski MJ, Chapman SA. Ondansetron-induced aminotransferase level elevation: case report and review of the literature. Pharmacotherapy 2008;28:1542-6
   PubMed Web of Science ®Google Scholar
• Müller J, Kralovánszky J, Adleff V, et al. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. Anticancer Res 2008;28:3051-4
   PubMed Web of Science ®Google Scholar
• Thia TJ, Tan HH, Chuah TH, et al. Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. Singapore Med J 2008;49:e86-9
   PubMed Web of Science ®Google Scholar
• Khokhar OS, Farhadi A, McGrail L, Lewis JH. Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent recativation. Chemotherapy 2009;55:69-75
   PubMed Web of Science ®Google Scholar
• El-Naggar MH, Helmy A, Moawad M, et al. Late-onset rosiglitazone-associated acute liver failure in a patient with Hodgkin′s lymphoma. Ann Pharmacother 2008;42:713-8
   PubMed Web of Science ®Google Scholar